Breast Neoplasms

Oncology·MeSH: Breast Neoplasms

Prevalence

287.0 / 100K

Incidence

128.0 / 100K/yr

33 drugs in development·12 companies·36 clinical trials

Drug Pipeline by Phase

Phase 3(11)

Phase 2(11)

Drug	Company
-endoxifen	ATOSSA THERAPEUTICS, INC. (ATOS)
350 mg leronlimab	CytoDyn Inc. (CYDY)
525 mg leronlimab	CytoDyn Inc. (CYDY)
700 mg leronlimab	CytoDyn Inc. (CYDY)
disitamab vedotin	PFIZER INC (PFE)
Eribulin	BioNTech SE (BNTX)
GNRH-A Goserelin	ELI LILLY & Co (LLY)
goserelin	ELI LILLY & Co (LLY)
goserelin	ATOSSA THERAPEUTICS, INC. (ATOS)
Iza-bren	Merus N.V. (MRUS)
Oleclumab	ASTRAZENECA PLC (AZN)

Phase 1(7)

Drug	Company
[68ga]ga-dwj155	Novartis AG (NVS)
elacestrant	STEMLINE THERAPEUTICS INC (STML)
Imlunestrant	ELI LILLY & Co (LLY)
ly3484356	ELI LILLY & Co (LLY)
LY4257496	ELI LILLY & Co (LLY)
Pumitamig	Merus N.V. (MRUS)
Tucatinib	Merck & Co., Inc. (MRK)

Unknown(2)

Drug	Company
et mono ± lhrh	NOVARTIS AG (NVSEF)
et mono ± lhrh	Novartis AG (NVS)

Phase 1/Phase 2(1)

Drug	Company
Pumitamig	BioNTech SE (BNTX)

Phase 2/Phase 3(1)

Drug	Company
iza-bren	BRISTOL MYERS SQUIBB CO (BMY)

BioSniper tracks 33 drugs in development for Breast Neoplasms across 12 companies.

There are 36 clinical trials targeting Breast Neoplasms tracked by BioSniper.

The estimated prevalence of Breast Neoplasms is approximately 287.0 per 100,000 population.

Full trial data, competitive analysis, and AI-powered pipeline tracking.